Trial
NCT05676697
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
YL-Pharma
Condition
Autoimmune Hemolytic Anemia
Intervention
Linperlisib
Why stopped
Did not meet the anticipated outcome.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-11